The recent attempt by 23andMe CEO Anne Wojcicki to take the genetic testing company private almost makes sequencing DNA look easy, given the complexity and potential conflicts inherent in insider offers.

Take-private deals by CEOs or other insiders may be subject to a more stringent judicial standard of review, requiring different procedural safeguards such as an independent special committee of the board and heightened public disclosure requirements, said Andrew Elken, an M&A partner at Latham & Watkins.